title: Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effect of risedronate treatment on OPG, C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), deoxypyridinoline (DPD), and to establish the correlation of OPG levels with other bone turnover markers.
  
  
  METHODS
  Eighty postmenopausal osteoporotic patients were randomized into two groups. In the first group, 37 patients received 35 mg of risedronate once a week, and 600 mg of elementary calcium with 400 IU of vitamin D per day. In the second group, 34 patients received only 600 mg of elementary calcium with 400 IU of vitamin D per day. OPG, OC, CTX and DPD levels were measured at baseline, then at 1, 3 and 6 months of treatment.
  
  
  RESULTS
  OPG levels were significantly reduced at 1 and 6 months of treatment in both the risedronate and control group (p&amp;lt;0.05, p&amp;lt;0.01, respectively), but no statistically significant difference was detected between the two groups (p&amp;gt;0.05). In the group treated with risedronate, a difference in CTX level was observed at 3 months of treatment, while a difference in DPD and OC levels were observed 6 months of treatment. The baseline OPG levels correlated with age, menopause duration and CTX levels. There was no correlation between OPG levels and the levels of the other markers.
  
  
  CONCLUSIONS
  Our results showed that using risedronate to treat postmenopausal osteoporosis causes no specific changes in OPG levels; thus, measurement of OPG levels as a marker may not be useful in the monitoring of bisphosphonate treatment.
authors.affiliation: Physical Medicine and Rehabilitation, Marmara University School of Medicine, Instanbul, Turkey. evrimkaradag4@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Gulseren
authors.forename: B
authors.initials: B
authors.lastname: Peyman
authors.forename: A
authors.initials: A
authors.lastname: Pinar
mesh_terms: D000368:Aged; D000596:Amino Acids / Q000096:biosynthesis; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001842:Bone and Bones / Q000378:metabolism; D024042:Collagen Type I / Q000096:biosynthesis; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000096:biosynthesis; D053244:Osteoprotegerin / Q000096:biosynthesis*; D017698:Postmenopause; D000068296:Risedronic Acid; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D000596:Amino Acids; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D053244:Osteoprotegerin; D015675:Osteocalcin; D014807:Vitamin D; C036020:deoxypyridinoline; D000068296:Risedronic Acid; D012968:Etidronic Acid